Eli Lilly upgrades full-year guidance due to solid growth in Q1
US-based pharmaceutical firm Eli Lilly has adjusted its revenue projection for the full year, with the new outlook of USD 28.8–29.3bn.
by marketwire, translated by daniel pedersen
US-based Eli Lilly is upgrading its 2022 revenue outlook in connection with the company’s first quarterly report on Thursday.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
